GNPX News and Press, Genprex Inc. From 09/20/21

Genprex (NASDAQ: GNPX) , a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, will be a featured presenter in both the CEO Roadshow Webinar series and the Benzinga Healthcare Small Cap Conference.Genprex president and...

Presentations to highlight Genprex’s novel gene therapy pipeline in cancer and diabetes Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX ), a clinical-stage gene therapy company focused on developing life-changing therapies ...

Drug-resistant superbugs have threatened human health for decades. The situation is getting worse because of the shortage of new antibiotics. But what if we changed the way we aim to treat them, and trained our cells to kill these invaders instead of relying on antibiotics to do the dirty work...

Genprex (NASDAQ: GNPX) , a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes, today announced that its president and CEO Rodney Varner will be participating in a webinar series with CEO Roadshow . The CEO Roadshow featu...

Series to highlight Genprex’s novel gene therapy pipeline in cancer and diabetes Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX ), a clinical-stage gene therapy company focused on developing life-changing therapies for pat...

Genprex Inc. (NASDAQ:GNPX) traded at a new 52-week low today of $2.81. So far today approximately 124,000 shares have been exchanged, as compared to an average 30-day volume of 700,000 shares. Genprex Inc. has overhead space with shares priced $2.91, or 32.2% below the average consensus ...

Genprex (NASDAQ: GNPX) , a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes, today announced that the U.S. Food and Drug Administration (“FDA”) has reviewed and confirmed all comments have been addressed r...

Genprex (GNPX) announces initiation of the company's phase 1/2 Acclaim-1 clinical trial for REQORSA immunogene therapy in combination with Tagrisso to treat non-small cell lung cancer following U.S. FDA review.The company has engaged its first clinical site for the trial, and Genprex is ...

Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX ), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that the U.S. Food and Drug Administration (FDA) has...

In recent years, biomedical research on topics surrounding longevity and aging has gained a tremendous amount of traction. The biotech industry as well as major pharmaceutical companies, have also jumped onto the bandwagon of discovering ways to alter and reverse the aging process. Currently, ...